- 1PharmaConflict erupts between employees of Takeda, Shire during merger
- 2PharmaWill Gilead enter the autoimmune diseases market?
- 3PharmaTakeda’s Zejula poised to change local ovarian cancer treatment market
- 4Pharma‘FDA likely to OK 11 blockbuster candidates in August’
- 5Pharma'Daewoong risk' could put a damper on AbbVie-Allergan mega-merger
- 6BioSamsung BioLogics’ fate remains uncertain amid litigating ups and downs
- 7PharmaSillajen likely to scrap global P3 trials for Pexa-Vec